Silicon Nanoneedle Patches for Painless, Sustained Treatment of Macular Degeneration
ACS Biomaterials Science & Engineering · 2026
DOI: 10.1021/acsbiomaterials.5c01783 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2026. Verfasst von Van Phuc Nguyen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland 21287, United States. Hauptthemen laut MEDLINE: Silicon, Macular Degeneration, Bevacizumab, Angiogenesis Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NEI NIH HHS, International Retinal Research Foundation, National Eye Institute.
Abstract (Originalsprache)
Choroidal neovascularization (CNV) represents a major cause of vision loss in various retinal diseases such as age-related macular degeneration (AMD). Current treatment involves frequent, often monthly, eye injections. The development of minimally invasive, long-term, painless, and effective ocular drug delivery systems is crucial for advancing the treatment of AMD. This study explores a novel method that integrates controllably bioresorbable silicon nanoneedles loaded with bevacizumab (Si NNs-Bev) on a tear-soluble subconjunctival patch for sustained, 1 year ocular drug delivery. The Si NNs-Bev embed into the sclera in a minimally invasive manner, undergoing controlled degradation over one year. This approach facilitates the sustained release of therapeutic agents, enhancing treatment efficacy and reducing treatment burden. Si NNs-Bev for the treatment of CNV are validated in a rabbit model of AMD. The SiNN-Bev patch achieved a sustained therapeutic effect on CNV regression, with a mean reduction of 82% by 4 months that is persistent for at least 1 year with minimal recurrence, which is consistent with the localized drug delivery mechanism facilitated by the transscleral microneedles. These preliminary findings underscore the potential of SiNNs as a platform technology for long-term, sustained ocular therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland 21287, United States.
- Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan 48105, United States.
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana 47907, United States.
- Ophthalmology Department, Fujian Provincial Hospital, Fuzhou, Fujian 350001, China.
- Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan, Ann Arbor, Michigan 48109, United States.
- School of Mechanical Engineering, Purdue University, West Lafayette, Indiana 47907, United States.
ORCID-Profile: Van Phuc Nguyen, Chi Hwan Lee, Yannis M Paulus
Förderung
- NEI NIH HHS
- International Retinal Research Foundation
- National Eye Institute
- Alcon Research Institute
- Ministry of Trade, Industry and Energy
- Johns Hopkins University
- Korea Institute for Advancement of Technology
Zitieren
APA
Nguyen, V. P., Jeong, J., Zhe, J., Zheng, M., Lee, J., Tran, K., Wei, Z., Lee, C. H., & Paulus, Y. M. (2026). Silicon Nanoneedle Patches for Painless, Sustained Treatment of Macular Degeneration. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.5c01783
Vancouver
Nguyen VP, Jeong J, Zhe J, Zheng M, Lee J, Tran K, et al. Silicon Nanoneedle Patches for Painless, Sustained Treatment of Macular Degeneration. ACS Biomaterials Science & Engineering. 2026. doi:10.1021/acsbiomaterials.5c01783
BibTeX
@article{Nguyen2026,
author = {Nguyen, Van Phuc and Jeong, Jinheon and Zhe, Josh and Zheng, Mi and Lee, Junsang and Tran, Khoi and Wei, Zhuying and Lee, Chi Hwan and Paulus, Yannis M},
title = {Silicon Nanoneedle Patches for Painless, Sustained Treatment of Macular Degeneration},
journal = {ACS Biomaterials Science & Engineering},
year = {2026},
doi = {10.1021/acsbiomaterials.5c01783}
}
EUVIMED